对于血管再生基因治疗的Codon优化和de novo合成的E-Selectin/AAV2剂量反应研究
Francesca A Voza1, Barry J Byrne2, Yulexi Y Ortiz1
1DeWitt Daughtry Family Department of Surgery, University of Miami School of Medicine, Miami, FL.
Annals of surgery
|July 8, 2024
概括
这项研究确定了E-Selectin/AAV2基因治疗治疗慢性四肢缺血症的最佳剂量. 每只动物的2 × 10 ^ 11载体基因组剂量显示,四肢 perfusion 和功能显著改善,没有毒性.
科学领域:
- 基因治疗 基因治疗
- 血管生物学 血管生物学
- 再生医学是一种再生医学.
背景情况:
- 慢性肢体威胁性缺血需要创新的治疗方法.
- 基因治疗提供了一个有前途的治疗途径.
- 确定最佳的基因传递剂量对于临床转化至关重要.
研究的目的:
- 为了研究一个编码子优化的E-Selectin/AAV2载体的剂量反应关系.
- 为研究新药 (IND) 准备,使研究能够进行临床试验.
- 在临床前的缺血病模型中评估E-Sel/AAV2的疗效和安全性.
主要方法:
- 开发和合成了一个编码子优化的E-Selectin/AAV2 (E-Sel/AAV2) 矢量.
- 在体外 (流细胞计) 和体内 (RT-qPCR) 评估基因表达.
- 在诱导肢体缺血的小鼠中进行了剂量反应研究,测试剂量从2 × 10^9 VG到2 × 10^11 VG.
主要成果:
- 与野生类型相比,经过编优化的E-Sel/AAV2表现出优越的表达.
- 最高剂量 (2 × 10 ^ 11 VG) 显著改善了四肢输液,减少了,增强了功能恢复,并促进了新血管.
- 在所有测试剂量中没有观察到显著的毒性.
结论:
- E-Sel/AAV2血管再生基因疗法有效改善缺血后肢输液和功能.
- 已确定E-Sel/AAV2的有效剂量为2 × 10 ^ 11VG,通过肌肉内注射.
- 这项研究为推进E-Sel/AAV2临床应用提供了关键数据.
更多相关视频
08:41Adeno-associated Virus-mediated Transgene Expression in Genetically Defined Neurons of the Spinal Cord
Published on: May 12, 2018
18.1K
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
Published on: October 18, 2022
4.5K
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
